Held by 6 specialist biotech funds
High Convergence# Signal Note: OrbiMed Initiates $46.2M Position in Axsome Therapeutics OrbiMed's new $46.2M stake signals confidence in Axsome's late-stage pipeline, particularly AXS-05 (dextromethorphan/bupropion) for major depressive disorder, which is awaiting FDA decision on a resubmitted NDA (likely Q1 2024).
AI analyst context — unlock full analysis
# Signal Note: Driehaus Initiates $40.3M AXSM Position Driehaus's entry into Axsome suggests conviction in the company's pipeline, likely centered on AXS-05 (dextromethorphan/bupropion combination) for major depressive disorder, which achieved primary endpoints in Phase 3 and is pending FDA decision (PDUFA timeline TBD). The growth-focused investor's $40.3M stake signals confidence in near-term regulatory clarity and commercial potential in a competitive antidepressant market where rapid-acting mechanisms remain underserved.
+ 4more — see how much conviction went in
See the Full Story